

# Data Quality

Nancy Lozon

Metropolitan Detroit Cancer Surveillance System

July 13, 2017

# Quality where to start

- DQP
- Data issues
- Quality Control for Abstractors
- Quality Control for Submission Hospitals
- Quality Control for Editors
  
- .....hmmmm

# DQP

- Yearly process -- a continuous process throughout the year
- Reports in DMS to help
  - Unknown/Invalid Census tract
  - Unknown laterality
  - SEER Data Quality marker Unknown Cause of Death
  - Cases lost to Follow up
  - Unknown/Illy defined site

# Data Quality Data Searches

- Sex is not 1 or 2
- County is 999 or Tri County code is a 9 -- to change to Macomb, Oakland or Wayne county, then it is reportable to SEER
- FIGO Grade vs FIGO Stage review
- Melanoma Breslow depth
- Prostate PSA
- Prostate grade 9

# Data Quality Data Searches

- Reporting Source = 3
- Unknown Race
- Review of HL7 records that were marked as benign at the initial screening

# Quality Control for Abstractors

- Discuss sites we are finding issues with to review
- Select the site, or sites
- Select 10-12 cases per abstractor
- Supervisor/Team Leader re-codes the cases from the documentation provided (don't have access to all hospitals EMR)
- QI Coordinator compiles and analyzes the results.
- Provide feedback to the abstractors

# Quality Control of Submission Hospitals

- Re-abstracting approach
- Encompass patient data, tumor data, staging data and treatment data.
- 50 cases are selected
- QI Coordinator reviews the cases, compiles and analyzes the information, provides feedback to the hospital

# Quality Control of Editors

- 4 Senior Editors (these Senior Editors have on average approximately 15 years experience)
- Assigned 3 or 4 editors to review
- Report 81B from SEER\*DMS is used
- Select 2-4 cases per week (experienced editors 2 cases, new editors 4 cases)
- QC on editors is weekly
- Review, provide feedback
- Put information on the grid, grid is for entire month



# Quality Control of Editors

- Set Accuracy rate at 97% for Editing
- Set Accuracy Rate at 97% for Consolidation/  
Mechanics
- If after 2 months editor is below 97%, increase QC
- Discuss the issues they are facing, work to improve their quality
- If after 2 more months, editor moves to “re-training”
- SEER Educate, one on one training with Senior Editors to help clarify issues

# MDCSS QC Grid

MDCSS Editing QA Review:

Reviewer

Analysis

Review dates:

## Visual editing

Cases reviewed		1
Cases with discrepancies		1
Data items / case		42
Total data items reviewed		42
Total number discrepancies		0
Overall discrepancy rate		0.0%
Overall accuracy rate		100.0%

## Consolidation/mechanics

Cases reviewed		1
Cases with discrepancies		1
Number data items/case		41
Total data items reviewed		41
Total number discrepancies		0
Overall discrepancy rate		0.0%
Overall accuracy rate		100.0%

<b>Accuracy rate goals</b>	
Visual editing	97.0%
Consolidation/mechanics	97.0%

## Data Item Results

Data Item	Discrepancies	
	#	%
Race	0	0.0%
Hispanic	0	0.0%
Date of Diagnosis	0	0.0%
Central sequence number	0	0.0%
Primary Site	0	0.0%
Laterality	0	0.0%
Diagnostic confirmation	0	0.0%
Histology	0	0.0%
Behavior	0	0.0%
Tumor Grade	0	0.0%
Dx/stage procedure	0	0.0%
Dx/procedure date	0	0.0%
Date therapy began	0	0.0%
Treatment status	0	0.0%
Reason no surgery	0	0.0%
Most definitive surgery date	0	0.0%
Surgery code	0	0.0%
Surgery date	0	0.0%
Scope reg LN surgery	0	0.0%
Scope reg LN surg date	0	0.0%
Surg other site	0	0.0%
Surg other site date	0	0.0%
Margins	0	0.0%
Surgical Approach 2010	0	0.0%
Reason no rad	0	0.0%
Radiation	0	0.0%
Radiation sequence	0	0.0%

Data Item	Discrepancies	
	#	%
Radiation start date	0	0.0%
Systemic date	0	0.0%
Systemic sequence	0	0.0%
Chemo	0	0.0%
Chemo date	0	0.0%
Hormone	0	0.0%
Hormone date	0	0.0%
BRM	0	0.0%
BRM date	0	0.0%
HemoEndo	0	0.0%
HemoEndo date	0	0.0%
Other	0	0.0%
Other date	0	0.0%
CS Size	0	0.0%
CS Extension	0	0.0%
CS Size/Extension Eval	0	0.0%
CS Lymph Nodes	0	0.0%
CS Lymph Node Eval	0	0.0%
CS Mets at DX	0	0.0%
CS Mets Eval	0	0.0%
Reg LN Positive	0	0.0%
Reg LN Examined	0	0.0%
Mets Bone	0	0.0%
Mets Brain	0	0.0%
Mets Liver	0	0.0%
Mets Lung	0	0.0%
Mets Distant LN	0	0.0%
Mets Other	0	0.0%

Data Item	Discrepancies	
	#	%
LVI	0	0.0%
SSF1 - 25	0	0.0%
SSF1 Prostate or Melanoma	0	0.0%
SEER Summary Stage	0	0.0%
Clinical T	0	0.0%
Clinical N	0	0.0%
Clinical M	0	0.0%
Clinical Descriptor	0	0.0%
Clinical Stage Group	0	0.0%
Clinical Staged by	0	0.0%
Pathologic T	0	0.0%
Pathologic N	0	0.0%
Pathologic M	0	0.0%
Pathologic Descriptor	0	0.0%
Pathologic Stage Group	0	0.0%
Pathologic Staged by	0	0.0%
Tumor Size Clinical	0	0.0%
Tumor Size Pathologic	0	0.0%
Tumor Size Summary	0	0.0%
Class of Case	0	0.0%
Cancer Status	0	0.0%
HL7 Close	0	0.0%
HL7 Link	0	0.0%
Diagnosing Facility	0	0.0%
View Source	0	0.0%
Reporting source	0	0.0%
Record consolidation	0	0.0%
Miscellaneous consolidation	0	0.0%

# Questions?

- Nancy Lozon, BS, CTR
- Assistant Director, Metropolitan Detroit Cancer Surveillance System
- 4100 John R Street MMo4EP
- Detroit, Mi 48201
- 313 578-4221
- [nancy.lozon@wayne.edu](mailto:nancy.lozon@wayne.edu)